Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Complete Response Letter
Pharma
Regeneron's Eylea franchise stumbles on several fronts in Q1
After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker.
Fraiser Kansteiner
Apr 29, 2025 2:50pm
Novo, Merck, Hengrui-Elevar—Fierce Pharma Asia
Mar 28, 2025 9:28am
FDA rejects Milestone’s nasal spray citing manufacturing issues
Mar 28, 2025 8:42am
FDA rejects Hengrui, Elevar's PD-1 cancer drug combo—again
Mar 21, 2025 3:25pm
Axsome secures hard-fought FDA nod for migraine drug Symbravo
Jan 31, 2025 8:18am
Atara hit with cell therapy clinical hold after FDA inspection
Jan 21, 2025 9:59am
